At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Effect of Volunteer-Engaged Lifestyle Optimisation Via ICOPE on Sarcopenia in Older Adults (VELO-S): A Randomised Controlled Trial
In Brief
A clinical study evaluating Volunteer-Engaged Lifestyle Optimisation via ICOPE for Sarcopenia program (VELO-S) and Attention control for Sarcopenia and 5 related conditions. Not yet recruiting, targeting 200 participants across 1 site.
Detailed Summary
Sarcopenia prevention and management are highly prioritised goals in the Healthy Ageing agenda. The study aims to: 1) evaluate the effects of the digital-enhanced, volunteer-engaged collaborative care pathway to improve sarcopenia, reduce fall risk, and increase health-related quality of life (HRQL) among community-dwelling older adults with risk of, or diagnosed with, sarcopenia; 2) evaluate whether the volunteers who received health coach capacity training and supported the intervention experienced health benefits across time; 3) explore the engagement experiences and perceived effects of elderly participants with sarcopenia during the program; 4) evaluate the intervention implementation process and effects from the perspectives of social care workers.
Study Details
Timeline
Interventions
A series of interactive lifestyle empowerment workshops will be conducted at community centres to translate the care plan into sustainable behavioural changes. In addition to one session for individualised care planning, five 90-minute, bi-weekly, in-person, volunteer-enhanced interactive workshops led by nurses will be delivered to equip older adults with knowledge and practical skills to manage sarcopenia. Before interactive workshops, a brief orientation and strategic planning session will focus on the health coach's role, introduce participants to them, and pair each participant with a coach. Participants will be assisted by a corresponding health coach throughout the 12-week intervention workshop.
The attention control group receives six session meeting covering topics unrelated to sarcopenia, it will be delivered in a small-group with comparable duration and frequency of contact and engagement to those in the intervention group